Zynex, Inc. Stock News

ENGLEWOOD, Colo. , Oct. 16, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 24, 2024 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended Se...

Analysts expect Zynex Inc (NASDAQ:ZYXI) to return to stronger growth in 2025, driven by product diversification, sales force expansion, and upcoming product launches. The company's strategic initiatives are seen as laying the groundwork for long-term success despite short-term hurdles.

Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard recently sat down with Proactive to discuss the medical device company's innovative solutions and impressive growth trajectory.   Sandgaard highlighted how Zynex has expanded from a one-person operation 28 years ago to a company with 1,200 employees and revenues reaching $200 million.

ENGLEWOOD, Colo. , Sept. 4, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming HC Wainwright Global Investment Conference, which is being held September 9-11, 2024.

Zynex Inc (NASDAQ:ZYXI) announced that its portable pain management device TensWave has achieved Food and Drug Administration (FDA) clearance. The prescription-only TensWave device aims to provide pain relief through TENS (Transcutaneous Electrical Nerve Stimulation) therapy, which the company highlighted has been clinically proven to reduce chronic and acute pain without needing medication.

ENGLEWOOD, Colo. , Sept. 3, 2024 /PRNewswire/ -- Zynex Inc. (NASDAQ: ZYXI), a leading medical technology company specializing in non-invasive medical devices for pain management and rehabilitation, today announced FDA clearance of its new TensWave device.

Growth versus value: It's a classic dilemma for investors. Choosing growth often demands a leap of faith—buying into a management team's vision of a significant commercial opportunity that may require patience and substantial financial investment to realize.

Zynex missed on second-quarter revenue and earnings, and guided down. However, some of the near-term weakness was by design, as the company is cutting costs.